Obinutuzumab
Cross-source consensus on Obinutuzumab from 1 sources and 6 claims.
1 sources · 6 claims
Uses
How it works
Benefits
Background
Evidence quality
Highlighted claims
- Obinutuzumab is a second-generation, glycoengineered, humanised anti-CD20 monoclonal antibody originally developed to overcome rituximab failure in B-cell malignancies. — Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial
- Obinutuzumab's glycoengineering produces more potent ADCC and greater induction of direct cell death compared with rituximab. — Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial
- Obinutuzumab binds CD20 at a different epitope than rituximab and is resistant to internalisation. — Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial
- Obinutuzumab has already met its primary endpoint in adult lupus nephritis. — Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial
- A single low-dose infusion of obinutuzumab at 300 mg/1.73 m² in 41 children with FR/SDNS achieved a median B-cell depletion duration of 8.3 months, consistently longer than prior rituximab. — Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial
- The OBIRINS trial aims to clarify whether obinutuzumab should replace or supplement rituximab earlier in the treatment pathway rather than being reserved for rituximab-refractory cases. — Obinutuzumab versus Rituximab to maintain remission in children with steroid-dependent and frequently relapsing nephrotic syndrome: the OBIRINS study protocol, a double-blind randomised controlled trial